## SI Unit

Hanyang University Guri Hospital
Department of Medicine
Dong Soo Han, M.D., AGAF

## SI Unit

- International System of Units
- international Committee for Weights and Measures
- Uniformity of quantities and units, minimize No. of unit
- constructed from 7 base units
- WHO recommend adoption of SI


## Base Units

| Qunatity | Base Unit Name | SI unit symbol |
| :--- | :--- | :---: |
| Length | 미터(meter) | m |
| Mass | 킬로그램(kilogram) | kg |
| Time | 초(second) | s |
| Electric current | 암페어(ampere) | A |
| Thermodynamic <br> temperature <br> Amount of <br> substance <br> Luminous intensity | 캘빈(Kelvin) | 콜(mole렐라(candela) |

## Derived Units

| Quantity | Name | SI symbol | Derived from |
| :---: | :--- | :---: | :---: |
| Area | square meter | $\mathrm{m}^{2}$ | $\mathrm{~m}^{2}$ |
| Speed, velocity | cubic meter | $\mathrm{m}^{3}$ | $\mathrm{~m}^{3}$ |
| Specific volumes | Cubic meter per kilogram | $\mathrm{m} / \mathrm{s}$ | $\mathrm{m} / \mathrm{s}$ |
| concentration | Mole per cubic meter | $\mathrm{m}^{3} / \mathrm{kg}$ | $\mathrm{mol} / \mathrm{m}^{3}$ |
| Frequency | hertz | $\mathrm{m} / \mathrm{mg}^{3}$ | $\mathrm{~mol} / \mathrm{m}^{3}$ |
| Density, mass density | Kilogram per cubic meter | $\mathrm{kg} / \mathrm{m}^{3}$ | s -1 |
| Force | newton | N | $\mathrm{kg} / \mathrm{m}^{3}$ |
| Pressure, stress | pascal | Pa | $\mathrm{kg} \cdot \mathrm{m}$ |
| Work, energy | joule | J |  |
| Luminous flux | Lumen | Lm |  |
| Power, radiant flux | Watt | W |  |
| Electric potential | Volt | V |  |
| Electric charge | Coulomb | C |  |
| Electric resistance | Ohm | $\Omega$ |  |
| Capacitance | Farad | F |  |
| Magnetic flux | Weber | Wb |  |
| Magnetic flux density | Tesla | T |  |
| Inductance | henry | H |  |



## Prefixs

| Factor | Prefix | Symbol |
| :---: | :--- | :---: |
| $10^{24}$ | yotta | Y |
| $10^{21}$ | zetta | Z |
| $10^{18}$ | exa | E |
| $10^{15}$ | peta | P |
| $10^{12}$ | tera | T |
| $10^{9}$ | giga | G |
| $10^{6}$ | mega | M |
| $10^{3}$ | Kilo | k |
| $10^{2}$ | hecto | h |
| $10^{1}$ | deca | da |
| $10^{-1}$ | deci | d |
| $10^{-2}$ | centi | c |
| $10^{-3}$ | milli | m |
| $10^{-6}$ | micro | $\mathrm{\mu}$ |
| $10^{-9}$ | nano | n |
| $10^{-12}$ | pico | p |
| $10^{-15}$ | femto | f |
| $10^{-18}$ | atto | a |
| $10^{-21}$ | zetto | z |

## Capitalization

- written lowercase roman when spell-out, leave space
- $135 \mathrm{~cm}, 250 \mathrm{~g}, 150 \mathrm{~W}, 23 \mathrm{Ix}, 370 \mathrm{~K}, 37.5^{\circ} \mathrm{C}$
- Units from proper name should be capitalized
- N for newton, K for kelvin, A for amphere
- ' L ' is prefer for liter than ' l '
-Abbreviation or symbols for units are also written lowercase
-(o) Five milliliters of supernatant was extracted.
- (x) Five mL of supernatant was extracted.
-Some SI prefix
- no space between prefix and units
- M for mega, m for milli,
- mg for milligram, MHz for megahertz
- one prefix only
-(0) 8 ng
- (x) $8 \mathrm{~m} \mu \mathrm{~g}$


## Capitalization

- Spellout when use ordinals, use arabic when two units of ordinal
- the sixth turn
- the $24^{\text {th }}$ anniversary
- The $5^{\text {th }}, 8^{\text {th }}$, and $10^{\text {th }}$ hypothesis were tested.
- Spellout when use the first phrase of sentence
- (o) Eighty doctors were ...
- (x) 80 doctors were ...
- (o) The 30-day...


## Products \& Quotients of Unit symbols

- The product of 2 or more units should be indicated by space or a raised multiplication dot.
-(o) newton meter or N m or $\mathrm{N} \cdot \mathrm{m}$
- (x) N X m
- Abbreviated \& nonabbreviated form should not be combined
-(x) newton-m or $\mathrm{N} \cdot \mathrm{meter}$
- Prefer to use abbreviated SI unit when denote a quantity of measurement
- (o) $50 \mathrm{~N} \cdot \mathrm{~m}$
-(x) 50 newton meter
- Quotient of unit is expressed by forward slash (/) or negative exponents
- (0) $\mu \mathrm{g} / \mathrm{L}$ or $\mu \mathrm{g} \mathrm{L}^{-1}$ or $\mu \mathrm{g} \cdot \mathrm{L}^{-1}$
-(x) $\mu \mathrm{g}$ per L
- Spell out in a quotient or in text, use per
- (o) joules per second (x) joules/second


## Products \& Quotients of Unit symbols

- use capital ' $X$ ' when express volume
- (o) $10 \times 35 \times 40 \mathrm{~mm}$, or 10 by 35 by 40 mm
- Do not use 'by' before range
- (o) Growth increased 0.1 to $0.3 \mathrm{~g} / \mathrm{d}$
- (x) Growth increased by 0.1 to $0.3 \mathrm{~g} / \mathrm{d}$


## Format, style, and Punctuation

- Exponents
-(o) $\mathrm{m}^{2} \quad(\mathrm{x})$ sq m
- Plurals; unit symbols are not expressed in the plural form.
- (o) $1 \mathrm{~L}, \quad 70 \mathrm{~L}, \quad 1 \mathrm{~g}, \quad 1500 \mathrm{~g}$
- (x) 1 Ls 70 Ls, 1 gs, 1500 gs
- Subject-Verb Agreement;
- unit measurement are treated as collective singular noun
- To control fever, 500mg of Tylenol was [not were] administered ...
- Beginning of Sentence, title, Subtitle
- A unit of measure that follows a number at the beginning of a sentence, title should not be abbreviated.


## Format, style, and Punctuation

- Avoid placing other words between 2 or more SI symbol
larval density averaged $30.2 \mathrm{~g} / \mathrm{m}^{2}$
(x) 30.2 g of larvae $/ \mathrm{m}^{2}$ or 30.2 grams of larvae per square meter
$10 \mathrm{~m}^{3} / \mathrm{s}$ or Ten cubic meters per second,
(x) 10 cubic meters/s or $10 \mathrm{~m}^{3} / \mathrm{sec}$ ond or 10 cubic meters/second
- Abbreviations
- most units of measure are abbreviated used with numerals, but certain unit should be spelled out
(o) Lengths, in millimeters, were .... or Lengths (mm) were ...
(x) Lengths (in mm ) were ... .
- Punctuation
- Symbols or abbreviation units of measure are not followed by a period unless at the end of a sentence.
- The patient's weigh was 75 kg [not 75 kg .] and had increased by $10 \%$.
- Hyphens
- used to join 2 spelled-out units of measure
- when the combination used as an adjective
- an 8-L container a $10-\mathrm{mm}$ strip


## Use of numerals with Units

-Spacing

- full space should appear between arabic numeral
- except $\%,{ }^{\circ}$, and normal and molar solutions
- $140 \mathrm{nmol} / \mathrm{L}$ (not $140 \mathrm{nmol/L}$ ), $125 \mathrm{~mm} \mathrm{Hg}, 40 \%$ adherence rate
- $45^{\circ}$ angle, temperature of $37.5^{\circ} \mathrm{C}$
- Expressing Quantities
- use only numbers between 0.1 and 1000
- Use appropriate prefix; 0.003 mL is expressed as $3 \mu \mathrm{~L}$
- Decimal format
- numeric values less than 1 require placement of 0 before the decimal
- (o) 0.123 ( $x$ ) . 123
- some static values are reported without the use of 0 before decimal
- $\mathrm{P}<.001$
- fraction should not be used with SI units.
-(o) $2.5 \mathrm{~kg} \quad(\mathrm{x}) 2^{1 / 2} \mathrm{~kg}$
- Mixed fraction occasionally used in the text


## Use of numerals with Units

- Number spacing
- SI does not use commas in number
-(o) 1234123456
- (x) 1,234 123,456
- 4 digit are expressed without spacing in postal code, page number, registration identifier
- Eg) Protocol 00005876
-Multiplication of numbers
- should be indicated by the multiplication sign ( x )
- used to express are, volume, matrix, magnification


## Symbols and expression

- Set off common mathematical operators all the equality symbols from variables and number by a space or thin space. When the symbols are modifying a number than serving operators, close them up to numeral
$\bullet+2.5$ difference , 40X lens objectives
- $x<y<z$
- Don not use operator symbols between 2 words
- (0) at greater than $-2^{\circ} \mathrm{C}$
- (x) at $>-2{ }^{\circ} \mathrm{C}$
- (o) the target zone equals the optimum plus
- (x) the target zone $=$ the optimum +
- Close up the center dot, product dot indicating multiplication
- Wavy lines are used to approximate line
-Symbol for vector are lowercase letter set in bold upright, not italic; the scalar are lowercase letter in italic
- aggregation or fence
- mathematics \{[( )]\}, prose or non-mathematics ([ \{ \}])
-예제 1-


#### Abstract

A complete blood count revealed a white-cell count of 5400 per cubic millimeter, with a differential count of $69 \%$ granulocytes, $16 \%$ lymphocytes, $12 \%$ monocytes, $2.5 \%$ eosinophils, and $0.1 \%$ basophils. The hemoglobin level was 12.3 g per deciliter ( 7.6 mmol per liter) , and the platelet count was 212,000 per cubic millimeter. The serum creatinine level was 1.1 mg per deciliter ( $97.2 \mu \mathrm{~mol}$ per liter), and the urea nitrogen level was 11 mg per deciliter ( 3.9 mmol per liter). The results of liver-function tests, the erythrocyte sedimentation rate, and the C-reactive protein level were normal. Testing for HIV was negative. A chest radiograph (Fig. 1) revealed a left lower-lobe cavity with an


## -SI단위를 존중하는 NEJM-

A complete blood count revealed a white-cell count of 5400 per cubic millimeter, with a differential count of $69 \%$ granulocytes, $16 \%$ lymphocytes, $12 \%$ nonocytes, $2.5 \%$ eosinophils, and $0.1 \%$ basophils. The hemoglobin level was 12.3 g per deciliter ( 7.6 mmol per liter) and the platelet count was 212,000 per cubic millimeter. The serum creatinine level was 1.1 mg per deciliter ( $97.2 \mu \mathrm{~mol}$ per liter), and the urea nitrogen level was 11 mg per deciliter ( 3.9 mmol per liter). The results of liver-function tests, the erythrocyte sedimentation rate, and the C-reactive protein level were normal. Testing for HIV was negative. A chest radiograph (Fig. 1) revealed a left lower-lobe cavity with an

## -SI단위를 존중하는 NEJM-


#### Abstract

A complete blood count revealed a white-cell count of 5400 per cubic millimeten, with a differential count of $69 \%$ granulocytes, $16 \%$ lymphocytes, $12 \%$ monocytes, $2.5 \%$ eosinophils, and $0.1 \%$ basophils. The hemoglobin level was 12.3 g per deciliter ( 7.6 mmol per liter), and the platelet count was 212,000 per cubic millimeter. The serum creatinine level was 1.1 mg per deciliter ( $97.2 \mu \mathrm{~mol}$ per liter), and the urea nitrogen level was 11 mg per deciliter ( 3.9 mmol per liter). The results of liver-function tests, the erythrocyte sedimentation rate, and the C-reactive protein level were normal. Testing for HIV was negative. A chest radiograph (Fig. 1) revealed a left lower-lobe cavity with an


Results At hospitals performing at least 100 on-pump CABG operations (82 446 cases at 408 sites), the rates of blood transfusion ranged from $7.8 \%$ to $92.8 \%$ for RBCs, $0 \%$ to $97.5 \%$ for fresh-frozen plasma, and $0.4 \%$ to $90.4 \%$ for platelets. Multivariable analysis including data from all 798 sites (102470 cases) revealed that after adjustment for patient-level risk factors, hospital transfusion rates varied by geographic location ( $P=.007$ ), academic status ( $P=.03$ ), and hospital volume ( $P<.001$ ). However, these 3 hospital characteristics combined only explained $11.1 \%$ of the variation in hospital risk-adjusted RBC usage. Case mix explained $20.1 \%$ of the variation between hospitals in RBC usage.

Results Among women following advanced cancer diagnosis compared with controls, at least 1 screening mammogram was received by $8.9 \%$ ( $95 \%$ confidence interval [Cl], 8.6\%-9.1\%) vs 22.0\% (95\% CI, 21.7\%-22.5\%); Papanicolaou test screening was received by $5.8 \%$ ( $95 \% \mathrm{CI}, 5.6 \%-6.1 \%$ ) vs $12.5 \%$ ( $95 \% \mathrm{CI}, 12.2 \%-$ $12.8 \%$ ). Among men following advanced cancer diagnosis compared with controls, PSA test was received by $15.0 \%$ ( $95 \% \mathrm{Cl}, 14.7 \%-15.3 \%$ ) vs $27.2 \%$ ( $95 \% \mathrm{Cl}, 26.8 \%-$ $27.6 \%$ ). For all patients following advanced diagnosis compared with controls, lower Gl endoscopy was received by $1.7 \%$ ( $95 \% \mathrm{CI}, 1.6 \%-1.8 \%$ ) vs $4.7 \% ~(95 \% \mathrm{CI}, 4.6 \%-$ $4.9 \%$ ). Screening was more frequent among patients with a recent history of screening ( $16.2 \%$ [ $95 \% \mathrm{CI}, 15.4 \%-16.9 \%$ ] of these patients had mammography, $14.7 \%$ [ $95 \% \mathrm{Cl}, 13.7 \%-15.6 \%$ ] had a Papanicolaou test, 23.3\% [95\% CI, 22.6\%-24.0\%] had a PSA test, and $6.1 \%[95 \% \mathrm{Cl}, 5.2 \%-7.0 \%]$ had lower GI endoscopy).

## -mmHg vs mm Hg-


#### Abstract

following a very low fat diet. Her physical exam now reveals a moderately overweight woman in marked distress as a result of pain and vomiting. Her vital signs include a temperature of $37.5^{\circ} \mathrm{C}$, pulse of 102 , blood pressure $154 / 79 \mathrm{~mm} \mathrm{Hg}$, respiratory rate of 18 , and body mass index of 36 . Her physical


Ann Intern Med 2010

The change from baseline in the systolic blood pressure at 24 months wa $\$-2.0 \mathrm{~mm} \mathrm{Hg}$ in the everolimus group and -1.5 mm Hg in the placebo group ( $\mathrm{P}=0.76$ ); the corresponding changes in diastolic blood pressure were -2.7 mm Hg and $-2.6 \mathrm{~mm} \mathrm{Hg}(\mathrm{P}=0.89)$.

$$
\begin{aligned}
& \text { 전증을 진단하였다(Fig. 3). 제 } 19 \text { 병일 호흡곤란을 호소하여 } \\
& \text { 시행한 동맥혈가스분석검사에서 } \mathrm{pH} 7.48, \mathrm{pCO}_{2} 42 \mathrm{mmHg}, \\
& \mathrm{pO}_{2} 62 \mathrm{mmHg}, \mathrm{HCO}_{3} 31 \mathrm{mmol} / \mathrm{L} \text {, 산소포화도 } 93 \% \text { 였고 응급 } \\
& \text { 으로 시행한 폐색전증 CT에서 우하엽과 우중엽 폐동맥 내 } \\
& \text { 에 충만결손을 보여 폐혈관색전증을 진단하고 헤파린을 정 } \\
& \text { 주하였다(Fig. 4). 폐혈전색전증의 원인을 찻기 위해 시행한 }
\end{aligned}
$$

국내 학술지

## -학술지마다 표기방식이 다르다-

Diverticulosis and therefore diverticulitis are increasing, what consequently increases complication rate. The prevalence of perforated sigmoid in diverticular disease in the western countries has increased from 2.4/100.000 in 1986 to $3.8 / 100.000$ in $2000 .{ }^{1}$ Another distressing factor is that during the last 20 years, standardized annual age rates of admission and surgical intervention have increased by $16 \%$ from 20.1/100.00 to $23.2 / 100.000$, whereas in-patient and population mortality remained unchanged. ${ }^{2}$

> The major hypothesis concerning the propensity to form diverticula focuses on dietary fibre ${ }^{9,13,15}$ Most studies support a strong inverse relationship between population fibre intake and the prevalence of diverticulosis. One study of approximately 47000 men found a relative risk of 0.58 for the presence of diverticulosis comparing the quintile with the highest average fibre intake with the quintile with the lowest intake. ${ }^{15}$

Alim Phar Ther 2007

Ann Intern Med 2007

## -각각 다른 p 값 표기-


#### Abstract

able analysis including data from all 798 sites ( 102470 cases) revealed that after adjustment for patient-level risk factors, hospital transfusion rates varied by geographic location $(P=.007)$, academic status ( $P=.03$ ), and hospital volume ( $P<.001$ ). Howin hospital risk-adjusted RBC usage. Case mix explained $20.1 \%$ of the variation between hospitals in RBC usage.


```
stroke risk increased among participants with an eGFR
<60 ml/min/1.73 m2 (relative risk 1.43, 95% confidence
interval 1.31 to 1.57; P(0.001) but not among those with
an eGFR of 60-90 ml/min/1.73 m}\mp@subsup{}{}{2}(1.07,0.98 to 1.17
```

Ann Intern Med 2010

terlipressin patients experienced combined partial re-
Gastroenterology 2010 sponse or treatment success as compared with placebo ( $16 / 56,29 \%$ vs $10 / 56,18 \%$, respectively; $P=.181$ ). Conversely, a greater number of placebo patients experienced
population (an increase with fidaxomicin of 10.5 percentage points; $95 \%$ CI, 3.1 to $17.7 ; \mathrm{P}=0.006$ )

NEJM 2010 and $77.7 \%$ (206 of 265 patients) versus $\overline{67.1 \% ~(190}$ of 283) in the per-protocol population (an increase

## 수식, 연산, 공식의 사용

$22.8 \pm 26.5 \mathrm{ng}$ per milliliter (range, 0.4 to 185.0). In addition, no plasma accumulation was found between day 1 and the end of therapy. The mean end-of-therapy fecal concentration of fidaxomicin was $1225.1 \pm 759.0 \mu \mathrm{~g}$ per gram (range, 31.7 to 4640.0), which is 4900 times as high as the minimum inhibitory concentration of $0.25 \mu \mathrm{~g}$ per milliliter for $90 \%$ of isolates against $C$. difficile.
of lymph-node metastases. ${ }^{16}$ Occult metastases may be more important in the case of larger tumors (combined hazard ratio $1.32 \times 1.40=1.85$ ) (Table 2). This observation was also noted in an analysis of the National Cancer Institute's Surveillance, Epidemiology, and End Results data with respect to the clinical significance of micrometastases. ${ }^{17}$ Occult metastases were more likely to
interval for vaccine efficacy to exclude 20\%. Vaccine efficacy was defined $a \$ 100 \% \times\left(1-\left[r_{v} / r_{p}\right]\right)$, with $r_{v}$, the incidence rate among vaccine recipients, defined as $C_{v}$, the number of primary efficacy cases among vaccine recipients, divided by $\tau_{v}$, the total person-years of follow-up among vaccine recipients. Similarly, $r_{p}$, the incidence rate among placebo recipients, was defined as $\mathrm{C}_{\mathrm{p}}$, the number of primary efficacy cases among placebo

[^0]
## 연산자 사용

formula, ${ }^{10}$ of 30 to 89 ml per minute per $1.73 \mathrm{~m}^{2}$ of body-surface area) or stage I chronic kidney disease (i.e., estimated GFR $\geq 90 \mathrm{ml}$ per minute) plus an estimated single kidney volume exceeding 1000 ml . Exclusion criteria were subarachnoid bleeding, severe infection, life-threatening urinary tract or cyst infection, severe liver disease, cancer, hypercholesterolemia (i.e., total cholesterol level $\geq 352 \mathrm{mg}$ per deciliter [ 9.1 mmol per liter]), hypertriglyceridemia (i.e., triglyceride level $\geq 496 \mathrm{mg}$ per deciliter [ 5.6 mmol per liter]), thrombocytopenia (i.e., platelet count $\leq 100,000$
stroke risk increased among participants with an eGFR $\leq 60 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ (relative risk 1.43, $95 \%$ confidence interval 1.31 to 1.57 ; $\mathrm{P}<0.001$ ) but not among those with an eGFR of $60-90 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ (1.07, 0.98 to 1.17 ; $\mathrm{P}=0.15)$. Significant heterogeneity existed between estimates among patients with an eGFR $<60 \mathrm{ml} / \mathrm{min} / 1.73$ $\mathrm{m}^{2}$ ( $\mathrm{P}<0.001$ ). In subgroup analyses among participants with an eGFR $<60 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$, heterogeneity was significant in Asians compared with non-Asians (1.96, 1.73 to $2.23 \vee 1.25,1.16$ to $1.35 ; \mathrm{P}<0.001$ ), and those with an eGFR of $40-60 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2} v<40 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$


## 괄호 표현

## mathematics $\{[()]\}$, prose or non-mathematics ([\{ \}])

ing 1000 ml . Exclusion criteria were subarachnoid bleeding, severe infection, life-threatening urinary tract or cyst infection, severe liver disease, cancer, hypercholesterolemia (i.e., total cholesterol level $\geq 352 \mathrm{mg}$ per deciliter $[9.1 \mathrm{mmol}$ per liter]), hypertriglyceridemia (i.e., triglyceride level $\geq 496 \mathrm{mg}$ per deciliter [ 5.6 mmol per liter]), thrombocytopenia (i.e., platelet count $\leq 100,000$
ing out differences due to patient-level risk factors. A hospital's risk-adjusted RBC usage rate was calculated as $1 /\left\{1+\exp \left[-\left(\alpha+\beta_{\mathrm{j}}\right)\right]\right\}$, where the constant $\alpha$ was chosen to reflect the baseline probability of receiving RBCs for an "average" patient and $\beta_{\mathrm{j}}$ denotes the $j$-th hospital's random intercept parameter. Percentiles were based on the esti-

## -CONFIDENCE INTERVAL-

> against persistent infection with specific HPV types ranged from $78.7 \%$ for HPV- 16 ( $95 \%$ CI, 55.5 to 90.9 ) to $96.0 \%$ for HPV- 18 ( $95 \%$ CI, 75.6 to 99.9 ). The vaccine was also efficacious in reducing detection of DNA at any time for all four HPV types (efficacy, $44.7 \%$; $95 \%$ CI, 31.5 to 55.6 ) Reductions in DNA detection of individual HPV

```
least 25/30 days. Resting heart rate was reduced from
baseline levels in the \beta blocker groups at each assess-
ment (-10.6 (95% confidence interval -13.2 to -7.9)
beats}/\textrm{min}(\textrm{n}=89)\mathrm{ at month 5; -9.4 (-12.1 to -6.7)
beats}/\textrm{min}(\textrm{n}=76)\mathrm{ at month 10; -6.8 (-9.9 to -3.6)
beats/min ( }\textrm{n}=59\mathrm{ ) at month 16), but essentially
unchanged in the placebo groups (-1.1 (-3.7 to 1.5)
```

```
ceived an average daily dose of 9.8 mg
(95% CI, 8.8-10.8 mg), whereas the pla-
ceho groun_received_a_mean of 208.3
mg(95% CI, 163.1-253.5 mg) or an av-
erage daily dose of 10.4 mg (95% CI,
9.3-11.4 mg). For weeks 17 through 24,
12% (13 of 108) in the buprenorphine
implant group received a mean dose of
56.9 mg (95% CI, 29.2-84.6 mg) and
an average daily dose of 12.7 mg (95%
CI, 10.1-15.2 mg) for a median of 3
days, whereas 20% (1l of 55) in the pla-
cebo group received a mean of 175.8
```

tients have suggested that LDL-C lowering beneath the current target, generally to lower than $/ 0 \mathrm{mg} / \mathrm{dL}$, may be associated with improved outcomes in individuals with diabetes. ${ }^{8-18}$ (To convert cholesterol values to $\mathrm{mmol} / \mathrm{L}$, multiply by 0.0259 ). Several studies using statin therapy in high-risk patients with diabetes also have suggested that further reduction in CVD events may be achieved in individuals who are at or below current LDL-C targets. ${ }^{18-25}$ In addition, antihypertensive treatment to levels below recommended goals (systolic blood pressure $[\mathrm{SBP}]<130 \mathrm{~mm} \mathrm{Hg}$ ) may delay progression of microalbuminuria to clinical proteinuria in diabetes, ${ }^{26}$ but the utility of this target in preventing CVD has not been assessed. Because no studies have specifically evaluated the benefits and risks of aggressive treatment targets for both LDL-C and BP in individuals with diabetes, the optimal treatment targets remain elusive.
A large body of epidemiologic data in American Indians, a population with
institutes of Health, and all participating American Indian communities.

## Recruitment

Participants were 548 men and women with type 2 diabetes, aged 40 years or older, enrolled between May 2003 and July 2004 at 4 clinical centers in the United States: southwestern Oklahoma; Phoenix, Arizona; northeastern Arizona; and South Dakota. All participants were American Indians as defined by Indian Health Service criteria. ${ }^{30}$

The participants were randomized to the aggressive $(\mathrm{n}=276)$ or standard treatment group ( $\mathrm{n}=272$ ) using the urn method stratified by clinical center and sex.

Eligibility criteria included documented type 2 diabetes, ${ }^{31,32}$ plus LDL-C of at least $100 \mathrm{mg} / \mathrm{dL}$ and SBP greater than 130 mm Hg within the previous 12 months

Major exclusion criteria were characteristics that might preclude trial completion or confound the out-
aggressive and standard groups, respectively. Secondary goals were diastolic BP (DBP) of 75 mm Hg or lower and 85 mm Hg or lower, respectively. Step 1 drugs were angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), in case of intolerance to ACE inhibitors. Step 2 was use of hydrochlorothiazide. Steps 3 to 5 added calcium channel blockers, $\beta$-blockers, and then $\alpha$-blockers and other vasodilators. Treatment for DBP was at the physician's discretion once SBP target was reached.

The algorithm for achieving lipid goals was based on recommendations of the National Cholesterol Education Program Adult Treatment Panel III. , $^{6,33}$ Goals for LDL-C were $70 \mathrm{mg} / \mathrm{dL}$ or lower and $100 \mathrm{mg} / \mathrm{dL}$ or lower and non-high-density lipoprotein cholesterol (non-HDL-C) goals were $100 \mathrm{mg} / \mathrm{dL}$ or lower and $130 \mathrm{mg} / \mathrm{dL}$ or lower in the aggressive and standard groups, respectively. If lifestyle modification was unsuccessful, use of a statin drug was ini-

$a=$ atomic number
$b=$ mass number
$c=$ charge number
$d=$ in a molecular formula
tion of fluorine $18\left({ }^{18} \mathrm{~F}\right)$ fluorodeoxyglucose (11.1-17.9 mCi [411-662 MBql).

## Clinical trial number

> Because the data used in analyses of the STS ACSD represent a limited data set (no direct patient identifiers) that was originally collected for nonresearch purposes, and the investigators do not know the identity of individual patients, the analysis of these data was declared by the Duke University Health System Institutional Review Board to be research not involving human subjects and is therefore considered exempt (Duke University Health System Protocol 00005876 ).

## KAMJE workshop




[^0]:    ZS rats (tumor incidence, $100 \%$ vs $16.6 \%, P=7.8 \times$ $10^{-6}$; multiplicity, $11 \pm 3.8$ vs $0.5 \pm 0.3, P<.001$ ). Replenishing zinc led to reduced S100A8/A9 mRNA levels at both time points and a low tumorigenic outcome in ZR vs nonreplenished ZD rats (incidence, $100 \%$ vs $28.9 \% P=5.0 \times 10^{-5}$; multipli City, $11 \pm 3.8$ vs $0.6 \pm 0.4, P<.001$ ). Thus, esophageal SIOUA8/A9 mRNA levels were regulated by zinc and were associated directly with the risk of developing tumors in zinc-modulated rats.

